Cargando…

Therapeutic Options for the Management of Postprandial Glucose in Patients With Type 2 Diabetes on Basal Insulin

In Brief For patients with type 2 diabetes who require add-on therapy to metformin plus basal insulin, GLP-1 receptor agonists may be a favorable option because they effectively manage postprandial glucose, reduce body weight, and have an overall favorable safety profile compared to other agents. Gi...

Descripción completa

Detalles Bibliográficos
Autor principal:	Hinnen, Debbie A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2015
Materias:	Feature Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4608276/ https://www.ncbi.nlm.nih.gov/pubmed/26487791 http://dx.doi.org/10.2337/diaclin.33.4.175

Ejemplares similares

iGlarLixi: A New Once-Daily Fixed-Ratio Combination of Basal Insulin Glargine and Lixisenatide for the Management of Type 2 Diabetes
por: Hinnen, Debbie, et al.
Publicado: (2018)

Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know
por: Skolnik, Neil, et al.
Publicado: (2018)

How Similar Are Biosimilars? What Do Clinicians Need to Know About Biosimilar and Follow-On Insulins?
por: Triplitt, Curtis, et al.
Publicado: (2017)

Breaking Barriers With Basal Insulin Biosimilars in Type 2 Diabetes
por: Heller, Simon, et al.
Publicado: (2023)

Clinical Implications of Canagliflozin Treatment in Patients With Type 2 Diabetes
por: Valentine, Virginia, et al.
Publicado: (2015)

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
por: Hinnen, Deborah
Publicado: (2017)

Use of Flash Continuous Glucose Monitoring Is Associated With A1C Reduction in People With Type 2 Diabetes Treated With Basal Insulin or Noninsulin Therapy
por: Wright, Eugene E., et al.
Publicado: (2021)

Combined use of basal insulin analog and acarbose reduces postprandial glucose in patients with uncontrolled type 2 diabetes
por: Kim, Ji-Hyun, et al.
Publicado: (2015)

Initiation of iGlarLixi Versus Basal-Bolus Insulin in Adults With Type 2 Diabetes Advancing From Basal Insulin Therapy: The SoliComplex Real-World Study
por: Pantalone, Kevin M., et al.
Publicado: (2023)

Effects of Type 2 Diabetes on Insulin Secretion, Insulin Action, Glucose Effectiveness, and Postprandial Glucose Metabolism
por: Basu, Ananda, et al.
Publicado: (2009)

Postprandial Platelet Activation Is Related to Postprandial Plasma Insulin Rather Than Glucose in Patients With Type 2 Diabetes
por: Spectre, Galia, et al.
Publicado: (2012)

Therapeutic Inertia and Delays in Insulin Intensification in Type 2 Diabetes: A Literature Review
por: Gavin, James R., et al.
Publicado: (2023)

Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)
por: Edelman, Steven, et al.
Publicado: (2023)

Insulin Initiation and Titration in Patients With Type 2 Diabetes
por: Chun, Ji, et al.
Publicado: (2019)

Improving Sleep in Intensive Care Unit: An Overview of Diagnostic and Therapeutic Options
por: Tiruvoipati, Ravindranath, et al.
Publicado: (2019)

Update on Insulin Therapy for Type 2 Diabetes
por: Donner, Thomas, et al.
Publicado: (2012)

Adding GLP-1 Receptor Agonist Therapy to Basal Insulin for Postprandial Glucose Control
por: Rhinehart, Andrew S.
Publicado: (2015)

Effectiveness and Tolerability of Therapy With Once-Weekly Exenatide Versus Basal Insulin Among Injectable-Naive Patients With Type 2 Diabetes in a Real-World Setting in the United States
por: Loughlin, Anita M., et al.
Publicado: (2018)

Postprandial Hypertriglyceridemia Predicts Development of Insulin Resistance Glucose Intolerance and Type 2 Diabetes
por: Aslam, Mohammad, et al.
Publicado: (2016)

Optimizing Postprandial Glucose Management in Adults With Insulin-Requiring Diabetes: Report and Recommendations
por: Leahy, John (Jack) L, et al.
Publicado: (2019)

Achievement of Target A1C <7.0% (<53 mmol/mol) by U.S. Type 2 Diabetes Patients Treated With Basal Insulin in Both Randomized Controlled Trials and Clinical Practice
por: Blonde, Lawrence, et al.
Publicado: (2019)

A basal-bolus insulin regimen integrated microneedle patch for intraday postprandial glucose control
por: Chen, Bo Zhi, et al.
Publicado: (2020)

Achieving postprandial glucose control with lixisenatide improves glycemic control in patients with type 2 diabetes on basal insulin: a post-hoc analysis of pooled data
por: Davidson, Jaime A., et al.
Publicado: (2020)

Carbohydrate-last meal pattern lowers postprandial glucose and insulin excursions in type 2 diabetes
por: Shukla, Alpana P, et al.
Publicado: (2017)

Review of basal‐plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus
por: Raccah, D., et al.
Publicado: (2017)

Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial
por: Chaykin, Louis, et al.
Publicado: (2019)

The effects of postprandial glucose and insulin levels on postprandial endothelial function in subjects with normal glucose tolerance
por: Suzuki, Kazunari, et al.
Publicado: (2012)

Effect of High β-glucan Barley on Postprandial Blood Glucose and Insulin Levels in Type 2 Diabetic Patients
por: Fuse, Yukie, et al.
Publicado: (2020)

Survey Reveals Patient and Health Care Provider Experiences and Challenges With the Use of High Doses of Basal Insulin
por: Goldman, Jennifer D., et al.
Publicado: (2023)

Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial
por: Cho, Kyu Yong, et al.
Publicado: (2020)

Diabetes Numeracy and Blood Glucose Control: Association With Type of Diabetes and Source of Care
por: Zaugg, Stephanie D., et al.
Publicado: (2014)

Prevalence of postprandial hyperglycaemia in basal insulin-treated patients with type 2 diabetes mellitus with controlled fasting glycaemia and elevated glycosylated haemoglobin
por: Tinahones, Francisco J., et al.
Publicado: (2019)

Evaluating the Effect of U-500 Insulin Therapy on Glycemic Control in Veterans With Type 2 Diabetes
por: Granata, Joseph A., et al.
Publicado: (2015)

Impact of Diabetes-Specific Nutritional Formulas versus Oatmeal on Postprandial Glucose, Insulin, GLP-1 and Postprandial Lipidemia
por: Mottalib, Adham, et al.
Publicado: (2016)

Sodium–Glucose Cotransporter 2 Inhibitor Protection Against Adverse Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes
por: Shahady, Edward, et al.
Publicado: (2019)

Advances in Insulin Therapy: A Review of New Insulin Glargine 300 Units/mL in the Management of Diabetes
por: White, John R.
Publicado: (2016)

Effect of Glycemic Control on Chylomicron Metabolism and Correlation between Postprandial Metabolism of Plasma Glucose and Chylomicron in Patients with Type 2 Diabetes Treated with Basal-bolus Insulin Therapy with or without Vildagliptin
por: Okajima, Fumitaka, et al.
Publicado: (2017)

Short-Term Outcomes for Veterans Receiving Basal Insulin, Metformin, and a Sulfonylurea Who Are Started on a Third Noninsulin Agent Versus Prandial Insulin
por: Santeusanio, Andrew D., et al.
Publicado: (2018)

Diabetes Is Devastating, and Insulin Is a Death Sentence: Provider Perspectives of Diabetes Self-Management in Arab-American Patients
por: DiZazzo-Miller, Roseanne, et al.
Publicado: (2017)

Health Literacy, Glycemic Control, and Physician-Advised Glucose Self-Monitoring Use in Type 2 Diabetes
por: Alvarez, Paul M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vpt3tqb0o8069iv04b9h4a5euj